Efficacy of mefloquine and a mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru

American Journal of Tropical Medicine and Hygiene

Volumn 68, Issue 5, 2003, Pages 608-612

  Marquiiño, Wilmer ^a   Huilca, María H ^a   Calampa, Carlos ^b   Falconí, Eduardo ^a   Cabezas, César ^a   Naupay, Rubén ^b   Ruebush II, Trenton K ^c  

^a INSTITUTO NACIONAL DE SALUD   (Peru)

^b Hospital Regional de Loreto   (Peru)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CHLOROQUINE; FANSIDAR; MEFLOQUINE; PLASMOTRIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; SESQUITERPENE;

ADULT; ARTICLE; ASEXUAL REPRODUCTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; NONHUMAN; PARASITEMIA; PERU; PLASMODIUM FALCIPARUM; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE DRUG DOSE; TREATMENT FAILURE; ADOLESCENT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; MIDDLE AGED; PRESCHOOL CHILD; TREATMENT OUTCOME; VOMITING;

PLASMODIUM FALCIPARUM; PROTOZOA;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; MIDDLE AGED; PARASITEMIA; PERU; RECURRENCE; SESQUITERPENES; TREATMENT OUTCOME; VOMITING;

EID: 0038470885     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. World Health Organization, 1998. The Use of Artemisinin and its Derivatives as Anti-Malarial Drugs: Report of a Joint CTD/DMP/TDR Informal Consultation. Geneva: World Health Organization. WHO Document WHO/MAL/98.1086.
2. White NJ, 1998. Preventing antimalarial drug resistance through combinations. Drug Resist Updates 1: 3-9.
3. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ, 2000. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356: 297-302.
4. Pan American Health Organization, 1998. Evaluation of the Therapeutic Efficacy of Drugs for the Treatment of Uncomplicated Plasmodium falciparum Malaria in the Americas. Washington, DC: Pan American Health Organization. OPS/HCP/HCT/113/98.〈bok〉
5. Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DF, Peters W, 1986. Chemotherapy of Malaria. World Health Organization Monograph Series No 27, Geneva: World Health Organization.
6. Ministerio da Saúde, 2001. Fundação Nacional de Saúde, Manual de Terapêutica de Malária. Brasilia: Brazil.
7. de Souza JM, 1983. A phase II clinical trial of mefloquine in Brazilian male subjects. Bull World Health Organ 61: 815-820.
8. Cardoso BS, Dourado HV, Pinheiro MCN, Crescente JAB, Amoras WW, Baena J, Saraty S, 1996. Estudo da eficácia e tolerância do artesunato oral isolado e ern associação com mefloquina no tratamento da malária falciparum não complicada era área endêmica do Pará. Res Soc Bras Med Trop 29: 251-257.
9. Cerutti C, Durlacher RR, de Alencar FEC, Segurado AAC, Pang LW, 1999. In vivo efficacy of mefloquine for the treatment of falciparum malaria in Brazil. J Infect Dis 180: 2077-2080.
10. Price RN, Nosten F, Luxemburger C, Kham Am, Brockman A, Chongsuphajaisiddhi T, White NJ, 1995. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg 89: 523-527.
11. Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, 1996. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347: 1654-1658.
12. Simpson JA, Watkins ER, Price RN, Aarons L, Kyle DE, White NJ, 2000. Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother 44: 3414-3424.
13. Weidekamm E, Rüsing G, Caplain H, Sörgel F, Crevoisier C, 1998. Lack of bioequivalence of a generic mefloquine tablet with the standard product. Eur J Clin Pharmacol 54: 615-619.
14. Na-Bangchang K, Karbwang J, Palacios PAC, Ubalee R, Saengtersilapachai S, Wernsdorfer WH, 2000. Pharmacokinetics and bioequivalence evaluation of three commercial tablet formulations of mefloquine when given in combination with dihydroartemisinin in patients with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol 55: 743-748.
15. ter Kuile FO, Nosten F, Luxemburger C, Kyle D, Teja-Isavatharm P, Phaipun L, Price R, Chongsuphajaisiddhi T, White NJ, 1995. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3,673 patients. Bull World Health Organ 73: 631-642.
16. Luxemburger C, Price RN, Nosten F, ter Kuile FO, Chongsuphajaisiddhi T, White NJ, 1996. Mefloquine in infants and young children. Ann Trop Paediatr 16: 281-286.
17. Ministerio de Salud, 1999. Programa de Control de Malaria y Otras Enfermedades Metaxénicas, Política Nacional de Medicamentos para el Control de la Malaria en el Perú. Lima, Peru.
18. Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Pa Eh J, Chongsuphajaisiddhi T, White NJ, 1994. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 170: 971-977.
19. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, Chongsuphajaisiddhi T, White NJ, 1997. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 91: 574-577.
20. Watkins WM, Mosobo M, 1993. Treatment of Plasmodium falciparum malaria with PSD: selective pressure for resistance is a function of long elimination half life. Trans R Soc Trop Med Hyg 87: 75-78.